InflaRx坏疽性脓皮病三期数据将亮相2026皮肤科年会股价盘前异动

投资观察

Yesterday

**关键临床数据即将揭晓** InflaRx NV（NASDAQ: IFRX）宣布，其候选药物Vilobelimab针对坏疽性脓皮病（Pyoderma Gangrenosum）的三期临床试验结果，将于2026年美国皮肤病学会（AAD）年会上以"迟来突破"（Late-Breaker）口头报告形式公布。该会议定于2026年3月举行。

**罕见皮肤病赛道受关注** 坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。患者常面临剧烈疼痛、皮肤溃疡及高复发率，当前标准治疗依赖高剂量皮质类固醇和免疫抑制剂，副作用显著。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。

**新机制药物的商业化前景** 分析师指出，罕见皮肤病药物因其明确的患者群体和较高的定价空间，通常具备较强的商业化潜力。Vilobelimab若成功获批，不仅可填补治疗空白，也可能拓展至其他补体介导的炎症性疾病。不过，其商业前景仍需关注三期数据的完整性与监管机构的审评态度。

**市场反应与后续节点** 受此消息影响，InflaRx股价在盘前交易中呈现波动。投资者将密切关注2026年AAD年会上的数据披露，以及后续向FDA提交生物制剂许可申请（BLA）的时间表。若数据超预期，可能推动股价进一步上行。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180374787"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180374787\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180374787?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-03-18 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180374787","market":"us","top_or_hot":-1,"title":"InflaRx坏疽性脓皮病三期数据将亮相2026皮肤科年会 股价盘前异动","media":"投资观察","content":"<p>**关键临床数据即将揭晓**\nInflaRx NV（NASDAQ: IFRX）宣布，其候选药物Vilobelimab针对坏疽性脓皮病（Pyoderma Gangrenosum）的三期临床试验结果，将于2026年美国皮肤病学会（AAD）年会上以\"迟来突破\"（Late-Breaker）口头报告形式公布。该会议定于2026年3月举行。</p>\n<p>**罕见皮肤病赛道受关注**\n坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。患者常面临剧烈疼痛、皮肤溃疡及高复发率，当前标准治疗依赖高剂量皮质类固醇和免疫抑制剂，副作用显著。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。</p>\n<p>**新机制药物的商业化前景**\n分析师指出，罕见皮肤病药物因其明确的患者群体和较高的定价空间，通常具备较强的商业化潜力。Vilobelimab若成功获批，不仅可填补治疗空白，也可能拓展至其他补体介导的炎症性疾病。不过，其商业前景仍需关注三期数据的完整性与监管机构的审评态度。</p>\n<p>**市场反应与后续节点**\n受此消息影响，InflaRx股价在盘前交易中呈现波动。投资者将密切关注2026年AAD年会上的数据披露，以及后续向FDA提交生物制剂许可申请（BLA）的时间表。若数据超预期，可能推动股价进一步上行。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>InflaRx坏疽性脓皮病三期数据将亮相2026皮肤科年会 股价盘前异动</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInflaRx坏疽性脓皮病三期数据将亮相2026皮肤科年会 股价盘前异动\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1076224072\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">投资观察 </p>\n<p class=\"h-time\">2026-03-18 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>**关键临床数据即将揭晓**\nInflaRx NV（NASDAQ: IFRX）宣布，其候选药物Vilobelimab针对坏疽性脓皮病（Pyoderma Gangrenosum）的三期临床试验结果，将于2026年美国皮肤病学会（AAD）年会上以\"迟来突破\"（Late-Breaker）口头报告形式公布。该会议定于2026年3月举行。</p>\n<p>**罕见皮肤病赛道受关注**\n坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。患者常面临剧烈疼痛、皮肤溃疡及高复发率，当前标准治疗依赖高剂量皮质类固醇和免疫抑制剂，副作用显著。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。</p>\n<p>**新机制药物的商业化前景**\n分析师指出，罕见皮肤病药物因其明确的患者群体和较高的定价空间，通常具备较强的商业化潜力。Vilobelimab若成功获批，不仅可填补治疗空白，也可能拓展至其他补体介导的炎症性疾病。不过，其商业前景仍需关注三期数据的完整性与监管机构的审评态度。</p>\n<p>**市场反应与后续节点**\n受此消息影响，InflaRx股价在盘前交易中呈现波动。投资者将密切关注2026年AAD年会上的数据披露，以及后续向FDA提交生物制剂许可申请（BLA）的时间表。若数据超预期，可能推动股价进一步上行。</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1180374787","we_media_id":"1076224072","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180374787","pubTimestamp":1773836113,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"投资观察","introduction":"关注海外资本市场一手动态","home_visible":1,"id":"1076224072","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"InflaRx NV宣布，其候选药物Vilobelimab针对坏疽性脓皮病的三期临床试验结果，将于2026年美国皮肤病学会年会上以\"迟来突破\"口头报告形式公布。该会议定于2026年3月举行。坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。受此消息影响，InflaRx股价在盘前交易中呈现波动。若数据超预期，可能推动股价进一步上行。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4139":"生物科技","IFRX":"InflaRx N.V."},"translate_title":"InflaRx Pyoderma Gangrenosum Phase III Data to be Unveiled at 2026 Dermatology Annual Meeting Stock Price Premarket Movements","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IFRX":1},"content_text":"**关键临床数据即将揭晓**\nInflaRx NV（NASDAQ: IFRX）宣布，其候选药物Vilobelimab针对坏疽性脓皮病（Pyoderma Gangrenosum）的三期临床试验结果，将于2026年美国皮肤病学会（AAD）年会上以\"迟来突破\"（Late-Breaker）口头报告形式公布。该会议定于2026年3月举行。\n**罕见皮肤病赛道受关注**\n坏疽性脓皮病是一种罕见且严重的嗜中性皮肤病，全球尚无获批疗法。患者常面临剧烈疼痛、皮肤溃疡及高复发率，当前标准治疗依赖高剂量皮质类固醇和免疫抑制剂，副作用显著。Vilobelimab作为靶向C5a补体蛋白的单克隆抗体，通过抑制炎症通路控制病情，若三期数据积极，有望成为该领域首个靶向疗法。\n**新机制药物的商业化前景**\n分析师指出，罕见皮肤病药物因其明确的患者群体和较高的定价空间，通常具备较强的商业化潜力。Vilobelimab若成功获批，不仅可填补治疗空白，也可能拓展至其他补体介导的炎症性疾病。不过，其商业前景仍需关注三期数据的完整性与监管机构的审评态度。\n**市场反应与后续节点**\n受此消息影响，InflaRx股价在盘前交易中呈现波动。投资者将密切关注2026年AAD年会上的数据披露，以及后续向FDA提交生物制剂许可申请（BLA）的时间表。若数据超预期，可能推动股价进一步上行。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}